GATA结合蛋白3、性别决定相关基因簇2在乳腺癌中的研究进展
Research Progress of GATA Binding Protein 3, Sex Determination-Related Gene Cluster 2 in Breast Cancer
DOI: 10.12677/ACM.2023.13102314, PDF,    科研立项经费支持
作者: 蔺嘉楠, 王立中, 余银平, 蒋威华*：新疆医科大学附属肿瘤医院乳腺外科，新疆 乌鲁木齐
关键词: GATA3；SOX2；免疫组化；乳腺癌；GATA3； SOX2； Immunohistochemistry； Breast Cancer
摘要: 乳腺癌是女性发病率最高的恶性肿瘤，GATA3转录因子在调控细胞分化等生物学行为中发挥广泛作用，SOX2转录因子参与肿瘤细胞自我更新，维持干细胞特性等发展中扮演重要角色。但二者是否影响乳腺癌的表达及乳腺癌的诊断、治疗决策和预后等尚待研究。本文就GATA3、SOX2对乳腺癌表达的相关临床研究进展进行综述。
Abstract: Breast cancer is the malignant tumor with the highest incidence in women. GATA3 transcription factor plays a broad role in regulating biological behaviors such as cell differentiation. SOX2 tran-scription factor participates in the development of tumor cell self-renewal and maintaining stem cell characteristics. However, whether the two factors affect the expression and the diagnosis, treatment decision and prognosis of breast cancer remains to be studied. This review summarizes the progress of clinical studies of GATA3 and SOX2 on breast cancer expression.
文章引用：蔺嘉楠, 王立中, 余银平, 蒋威华. GATA结合蛋白3、性别决定相关基因簇2在乳腺癌中的研究进展[J]. 临床医学进展, 2023, 13(10): 16535-16542. https://doi.org/10.12677/ACM.2023.13102314

参考文献

[1] 李思佳, 李曼曼, 刘慧, 等. Ki-67表达在三阴性乳腺癌患者预后中价值分析[J]. 中国医师进修杂志, 2019, 42(5): 392-395. [Google Scholar] [CrossRef] 
[2] 刘佳静, 黄桂春, 王文艺, 等. 化疗联合PD-(L)1单抗治疗晚期三阴性乳腺癌的研究进展[J]. 现代肿瘤医学, 2023, 31(6): 1156-1161. [Google Scholar] [CrossRef] 
[3] Lionti, S., La Rocca, L., Nunnari, C.M. and Barresi, V. (2018) Strong Androgen Receptor Expression Is Not Useful in Distinguishing GATA3+ Metastases. Pathology Re-search and Practice, 214, 2110-2114. [Google Scholar] [CrossRef] [PubMed]
[4] 吴开良, 时倩倩, 杨壹羚, 等. GATA3在乳腺癌中的研究进展[J]. 中国现代医学杂志, 2021, 31(5): 34-38. [Google Scholar] [CrossRef] 
[5] Najafabadi, M.K., Mirzaeian, E., Montazerin, S.M., et al. (2021) Role of GATA3 in Tumor Diagnosis: A Review. Pathology Research and Practice, 226, Article ID: 153611. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, J., Zhao, X., Huang, R.Y., et al. (2021) The Role of GATA3 in Breast Cancer: An Updated Review. Current Chinese Science, 1, 608-615. [Google Scholar] [CrossRef] 
[7] Tsai, K.K., Chan, T.S. and Shaked, Y. (2019) Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. Journal of Clinical Medicine, 8, E702. [Google Scholar] [CrossRef] [PubMed]
[8] Sinh, A., et al. (2019) Enhanced Induction of Apoptosis in Ha-CaT Cells by Luteolin Encapsulated in PEGylated Liposomes-Role of Caspase-3/Caspase-14. Applied Biochemistry and Biotechnology, Part A. Enzyme Engineering and Biotechnology, 188, 147-164. [Google Scholar] [CrossRef] [PubMed]
[9] Shan, L., Li, X., Liu, L., et al. (2014) GATA3 Cooperates with PARP1 to Regulate CCND1 Transcription through Modulating Histone H1 Incorporation. Oncogene, 33, 3205-3216. [Google Scholar] [CrossRef] [PubMed]
[10] 江琪, 习一清, 魏蕾. LncRNA GATA3-AS1促进乳腺癌细胞的增殖迁移及其机制[J]. 医学新知, 2022, 32(2): 127-137. [Google Scholar] [CrossRef] 
[11] Schrijver, W., Schuurman, K., van Rossum, A., et al. (2018) FOXA1 Levels Are Decreased in Pleural Breast Cancer Metastases after Adjuvant Endocrine Therapy, and This Is Associated with Poor Outcome. Molecular Oncology, 12, 1884-1894. [Google Scholar] [CrossRef] [PubMed]
[12] 方煜彤, 张群琛, 洪超群, 等. 乳腺癌中miR-221、miR-222表达水平对GATA3和FOXA1蛋白的影响及其作用机制[J]. 癌变•畸变•突变, 2021, 33(6): 435-441, 460. [Google Scholar] [CrossRef] 
[13] Si, W.Z., Huang, W., Zheng, Y., et al. (2015) Dys-function of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis. Cancer Cell, 27, 822-836. [Google Scholar] [CrossRef] [PubMed]
[14] Kim, K.S., Kim, J., Oh, N., et al. (2018) ELK3-GATA3 Axis Modulates MDA-MB-231 Metastasis by Regulating Cell-Cell Adhesion-Related Genes. Biochemical and Biophysical Research Communications, 498, 509-515. [Google Scholar] [CrossRef] [PubMed]
[15] Chou, J., Lin, J.H., Brenot, A., et al. (2013) GATA3 Suppresses Metastasis and Modulates the Tumour Microenvironment by Regulating microRNA-29b Expression. Nature Cell Biolo-gy, 15, 201-213. [Google Scholar] [CrossRef] [PubMed]
[16] Desmedt, C., Zoppoli, G., Gundem, G., et al. (2016) Ge-nomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 34, 1872-1881. [Google Scholar] [CrossRef] 
[17] Martin, E.M., Orlando, K.A., Yokobori, K., et al. (2021) The Es-trogen Receptor/GATA3/FOXA1 Transcriptional Network: Lessons Learned from Breast Cancer. Current Opinion in Structural Biology, 71, 65-70. [Google Scholar] [CrossRef] [PubMed]
[18] Takaku, M., Grimm, S.A., Roberts, J.D., et al. (2018) GATA3 Zinc Finger 2 Mutations Reprogram the Breast Cancer Transcriptional Network. Nature Communications, 9, Article No. 1059. [Google Scholar] [CrossRef] [PubMed]
[19] 钱卫东, 沈兰芳, 王婷, 等. gata3基因表达与人乳腺肿瘤病理特征的相关性分析[J]. 陕西科技大学学报, 2019, 37(4): 40-45, 63. [Google Scholar] [CrossRef] 
[20] Karn, R. and Emerson, I.A. (2020) Breast Cancer Muta-tion in GATA3 Zinc Finger 1 Induces Conformational Changes Leading to the Closer Binding of ZnFn2 with a Wrapping Architecture. Journal of Biomolecular Structure and Dynamics, 38, 1810-1821. [Google Scholar] [CrossRef] [PubMed]
[21] 仲竹娟, 戚玉琴, 时潇洋. GATA3在乳腺非特殊类型浸润性导管癌中的表达及临床意义[J]. 南通大学学报(医学版), 2021, 41(1): 84-86. [Google Scholar] [CrossRef] 
[22] Tang, S.X., Yu, B.H., Xu, X.L., et al. (2017) Char-acterisation of GATA3 Expression in Invasive Breast Cancer: Differences in Histological Subtypes and Immunohisto-chemically Defined Molecular Subtypes. Journal of Clinical Pathology, 70, 926-934. [Google Scholar] [CrossRef] [PubMed]
[23] McDonald, T.M. and Epstein, J.I. (2021) Aberrant GATA3 Staining in Prostatic Adenocarcinoma. American Journal of Surgical Pathology, 45, 341-346. [Google Scholar] [CrossRef] 
[24] Byrne, D.J., Deb, S., Takano, E.A., et al. (2017) GATA3 Expression in Triple-Negative Breast Cancers. Histopathology, 71, 63-71. [Google Scholar] [CrossRef] [PubMed]
[25] 袁静萍, 吴娟, 余鑫鑫, 等. GATA3、MGB和GCDFP-15在乳腺癌中的病理诊断价值[J]. 中华内分泌外科杂志, 2020, 14(2): 94-99. [Google Scholar] [CrossRef] 
[26] Kimura, N., Shiga, K., Kaneko, K., et al. (2020) The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Para-ganglioma. Endocrine Pathology, 31, 95-100. [Google Scholar] [CrossRef] [PubMed]
[27] Boto, A. and Harigopal, M. (2018) Strong Androgen Receptor Expression Can Aid in Distinguishing GATA3+ Metastases. Human Pathology, 75, 63-70. [Google Scholar] [CrossRef] [PubMed]
[28] Malinee, M., Kumar, A., Hidaka, T., et al. (2019) Targeted Suppression of Metastasis Regulator Transcription Factor SOX2 in Various Cancer Cell Lines Using a Se-quence-Specific Designer Pyrrole-Imidazole Polyamide. Bioorganic & Medicinal Chemistry, 6, Article ID: 115248. [Google Scholar] [CrossRef] [PubMed]
[29] 李佳艺, 游雪叶, 叶煌阳, 等. 三阴乳腺癌原发灶和转移灶中ER-u36、EpCAM、SOX2的表达及临床意义[J]. 中国老年学杂志, 2017, 37(17): 4190-4192.
[30] Kamarlis, R.K., Lubis, M.N., Hernowo, B.S., et al. (2017) Immunoexpression of P63 and SOX2 in Triple-Negative Breast Cancers, In-donesia. F1000Research, 6, Article No. 1780. [Google Scholar] [CrossRef] 
[31] 张晶, 王崇杰, 门康, 等. 基于生物信息学方法分析SOX11与乳腺癌患者临床参数、预后的关系及其调控通路[J]. 山东医药, 2022, 62(11): 24-27. [Google Scholar] [CrossRef] 
[32] Wang, Y., Zhou, J., Wang, Z., et al. (2017) Upregulation of SOX2 Activated LncRNA PVTl Expression Promotes Breast Cancer Cell Growth and Inva-sion. Biochemical and Biophysical Research Communications, 493, 429-436. [Google Scholar] [CrossRef] [PubMed]
[33] Dey, A., Kundu, M., Das, S., Jena, B.C. and Mandal, M. (2022) Understanding the Function and Regulation of SOX2 for Its Therapeutic Potential in Breast Cancer. Biochimica et Bio-physica Acta (BBA)—Reviews on Cancer, 1877, Article ID: 188692. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, J., Lv, X., Wei, B., Gong, X. and Chen, L. (2022) CHD4 Mediates SOX2 Transcription through TRPS1 in Luminal Breast Cancer. Cell Signal, 100, Article ID: 110464. [Google Scholar] [CrossRef] [PubMed]
[35] 陆宇云, 黄梅, 石新蕾, 等. 2011至2020年乳腺癌干细胞Web of Science数据库的文献计量学与可视化分析[J]. 中国组织工程研究, 2021, 25(25): 4001-4008.
[36] Zhou, L., Zhao, L.C., Jiang, N., et al. (2017) MicroRNA miR-590-5p Inhibits Breast Cancer Cell Stemness and Metastasis by Targeting SOX2. European Review for Medical & Pharmacological Sciences, 21, 87-94.
[37] 牟雯君. SOX2对肿瘤微环境中巨噬细胞功能的影响与调节[D]: [硕士学位论文]. 天津: 南开大学, 2011.[CrossRef] 
[38] Zhou, C., Wang, D., Li, J., Wang, Q., Wo, L., Zhang, X., Hu, Z., et al. (2022) TGFB2-AS1 Inhibits Triple-Negative Breast Cancer Progression via Interaction with SMARCA4 and Regulating Its Targets TGFB2 and SOX2. Proceedings of the National Academy of Sciences of the United States of America, 119, e2117988119. [Google Scholar] [CrossRef] [PubMed]
[39] Dittmer, A. and Dittmer, J. (2020) Carcinoma-Associated Fibro-blasts Promote Growth of SOX2-Expressing Breast Cancer Cells. Cancers (Basel), 12, Article No. 3435. [Google Scholar] [CrossRef] [PubMed]
[40] Peng, W., Chang, L., Li, W., Liu, Y. and Zhang, M. (2022) OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice. Frontiers in Oncology, 12, Article ID: 781093. [Google Scholar] [CrossRef] [PubMed]
[41] 张鹏, 徐洪燕, 孙勇. SOX2和ABCC5在乳腺癌中的表达及与化疗敏感性的关系[J]. 河北医药, 2020, 42(5): 645-649. [Google Scholar] [CrossRef] 
[42] Tang, W., Zhang, X., Tan, W., et al. (2019) miR-145-5p Suppresses Breast Cancer Progression by Inhibiting SOX2. Journal of Surgical Research, 236, 278-287. [Google Scholar] [CrossRef] [PubMed]

为你推荐